Amendment 0001 RFQ3 NAD.pdf

This document is an amendment to solicitation HT9402-24-Q-9304 for the Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program. The purpose of the amendment is to add the NDC price list for Fasenra 10mg to the RFQ3 NAD. All other terms and conditions of the solicitation remain the same. The solicitation is for pharmaceutical agents across various drug classes that will be considered for placement on the DoD Uniform Formulary. The DoD Pharmacy and Therapeutics Committee will review newly approved drugs at their August 2024 meeting, including Duvyzat, Iqirvo, Myhibbin, Sitagliptan/Metformin, and Tyenne. The RFQ, including the UF BPA and UF ADP appendices, provides instructions, important deadlines, and points of contact. A pre-quotation teleconference is scheduled for July 10, 2024, and responses to clinical questions are due by the date stated in Part 2.3.